Drugs in the graveyard increase costs
This week we learned that Merck & Co. was ending the Phase III APECS study of Verubecestat (formerly known as MK-8931) for the treatment of prodromal Alzheimer Disease. Yet another drug in AD graveyard!!
This week we learned that Merck & Co. was ending the Phase III APECS study of Verubecestat (formerly known as MK-8931) for the treatment of prodromal Alzheimer Disease. Yet another drug in AD graveyard!!
What is Health Literacy?
Sometimes, when we think about a new app or technology that will be useful for improving health in African people, we don’t consider the applicability that this app will have.